| Old Articles: <Older 4661-4670 Newer> |
|---|
 |
The Motley Fool
March 17, 2008
Rich Duprey |
Foolish Forecast: Healthways Looking Ill In advance of earnings, analysts wonder if managed-care provider Healthways will meet its own scaled back expectations.   |
The Motley Fool
March 17, 2008
Brian Lawler |
Parsing the Details With Dendreon Development-stage drugmaker Dendreon announces that it is changing its pivotal phase 3 clinical trial for its lead drug. |
The Motley Fool
March 17, 2008
Brian Lawler |
The Panelling on Amgen's Walls One FDA panel ruling is a win, another is much less upsetting than investors feared. |
The Motley Fool
March 14, 2008
Rich Duprey |
No Point Man at Candela Activist hedge fund Third Point cuts its stake in the aesthetic laser maker Candela from 9% to only 3.5%. |
The Motley Fool
March 14, 2008
Brian Orelli |
ALS: The Disease That Kills Drugs Teva's Copaxone doesn't help patients with Lou Gehrig's disease. Investors, take note. |
The Motley Fool
March 14, 2008
Brian Orelli |
Weighing In on Obesity Drugs Could investing in drugmakers that produce weight-loss drugs help fatten your wallet? |
The Motley Fool
March 14, 2008
Stephen Albainy-Jenei |
The War on (the Cost of) Drugs Pharmaceutical companies could be hurt by countries disregarding drug patents. |
The Motley Fool
March 14, 2008
Brian Orelli |
No Slowdown for China's WuXi Chinese drug researcher and manufacturer WuXi signs more drug development deals and buys a U.S. manufacturing services company. |
The Motley Fool
March 13, 2008
Brian Orelli |
Progenics Down but Not Out Progenics Pharmaceuticals' drug to help patients after abdominal surgery fails in its phase 3 trial. Investors, take note. |
The Motley Fool
March 13, 2008
Stephen Albainy-Jenei |
Pfizer's Celebrex Aches and Pains The Court of Appeals for the Federal Circuit upholds a lower court's ruling that found Teva Pharmaceutical had infringed two of Pfizer's patents for Celebrex. |
| <Older 4661-4670 Newer> Return to current articles. |
